ALKEM LAB: CO & UNIT ENZENE BIOSCIENCES HAVE AGREED TO INVEST 26% EQUITY IN SUNSURE SOLARPARK FOR RENEWABLE ENERGY GENERATION, TOTALING RS. 1.95 CRORE

 17 Dec 2024 06:07 PM

ALKEM LAB: CO & UNIT ENZENE BIOSCIENCES HAVE AGREED TO INVEST 26% EQUITY IN SUNSURE SOLARPARK FOR RENEWABLE ENERGY GENERATION, TOTALING RS. 1.95 CRORE

Alkem Lab promoter buys sea-facing luxury apartment in Mumbai’s Worli for Rs 185 cr

 13 Dec 2024 05:15 PM

Seema Singh, part of Alkem Laboratories' promoter group, purchased a 14,000 sq ft luxury apartment on the 30th floor of Lodha Sea Face in Mumbai’s Worli for Rs 185 crore. This is the second-largest luxury apartment deal in Mumbai in 2024. Singh, wife of Alkem’s Executive Director, also received 9 car parking slots.

ALKEM LABS: CO SAYS NET-WORTH OF TRADE GENERIC BUSINESS OF THE CO AS ON MARCH 31, 2024, WAS ABOUT RS.519 CR || CONSIDERATION EXPECTED TO BE UP TO RS. 750 CR

 10 Dec 2024 12:57 PM

ALKEM LABS: CO SAYS NET-WORTH OF TRADE GENERIC BUSINESS OF THE CO AS ON MARCH 31, 2024, WAS ABOUT RS.519 CR || CONSIDERATION EXPECTED TO BE UP TO RS. 750 CR

ALKEM LABS: CO GETS APPROVAL TO TRANSFER ITS TRADE GENERICS BUSINESS TO ALKEM WELLNESS

 10 Dec 2024 12:56 PM

ALKEM LABS: CO GETS APPROVAL TO TRANSFER ITS TRADE GENERICS BUSINESS TO ALKEM WELLNESS

Stocks to buy today: SBI, ICICI Bank among top 9 trading ideas for 2 December 2024

 02 Dec 2024 09:15 AM

The Indian market is expected to trade higher on Monday, driven by positive global cues. Nifty futures gained 0.84% on Friday, and India VIX fell by over 5%. Options data suggests a trading range between 23,600 to 24,600, with immediate support at 24,000. Experts recommend various stocks for short-term trading, including Alkem Laboratories, SBI, and ICICI Bank.

InCred cuts Nifty50 blended index target to 25,327, upgrades pharma to overweight

 27 Nov 2024 03:00 PM

InCred Equities cut Nifty50 target to 25,327, expecting a correction phase. The brokerage upgraded its stance on pharma stocks like Cipla, Ipca, and Alkem Laboratories. The IT, capital goods, and pharma sectors outperformed during the recent correction. The overall market sentiment remains cautious due to weak macroeconomic conditions and potential EPS downgrades.

ALKEM LAB: TODAY 3PM MSCI GLOBAL INCLUSION EXPECTED IN FLOW: $201 MILLION (RS 16.68B)

 25 Nov 2024 02:49 PM

ALKEM LAB: TODAY 3PM MSCI GLOBAL INCLUSION EXPECTED IN FLOW: $201 MILLION (RS 16.68B)

Add Alkem Laboratories, target price Rs 6,180: HDFC Securities

 15 Nov 2024 09:11 AM

HDFC Securities recommends buying shares of Alkem Laboratories. They set a target price of Rs 6,180. The current market price is Rs 5,535. Alkem Laboratories' recent performance was slightly below expectations. However, the company expects growth in the Indian pharmaceutical market and improved profitability. HDFC Securities believes Alkem Laboratories will experience steady growth in the coming years.

ALKEM LABS: CO EXPECTS PRODUCTION TO BEGIN BY Q4 TO Q1 OF NEXT FINANCIAL YEAR, WITH NO SIGNIFICANT DELAY REPORTED AS OF NOW || ANOTHER PRODUCT LAUNCH IS EXPECTED IN Q3, WHICH HAS RECEIVED CGT WITH VANITY DAYS EXCLUSIVITY - CONCALL UPDATE

 14 Nov 2024 08:51 AM

ALKEM LABS: CO EXPECTS PRODUCTION TO BEGIN BY Q4 TO Q1 OF NEXT FINANCIAL YEAR, WITH NO SIGNIFICANT DELAY REPORTED AS OF NOW || ANOTHER PRODUCT LAUNCH IS EXPECTED IN Q3, WHICH HAS RECEIVED CGT WITH VANITY DAYS EXCLUSIVITY - CONCALL UPDATE

ALKEM LABS: CO IS GUIDING FOR AN IMPROVEMENT IN EBITDA MARGINS BY AT LEAST 100 BASIS POINTS EVERY YEAR || CO AIMS TO IMPROVE THE EBITDA MARGIN IN THE U.S. BUSINESS TO BE CLOSER TO THE OVERALL EBITDA MARGIN, WHICH IS EXPECTED TO BE AROUND 18.5% TO 19% - CONCALL UPDATE

 14 Nov 2024 08:49 AM

ALKEM LABS: CO IS GUIDING FOR AN IMPROVEMENT IN EBITDA MARGINS BY AT LEAST 100 BASIS POINTS EVERY YEAR || CO AIMS TO IMPROVE THE EBITDA MARGIN IN THE U.S. BUSINESS TO BE CLOSER TO THE OVERALL EBITDA MARGIN, WHICH IS EXPECTED TO BE AROUND 18.5% TO 19% - CONCALL UPDATE